Sustained >95% MTX reductions
91% (20/22) of patients who received VORAXAZE achieved a >95% reduction in plasma MTX concentrations within 15 minutes of administration that lasted for up to 8 days.1
VORAXAZE WORKS FAST AND LASTS1
At each post-VORAXAZE assessment time point, the median MTX concentration was <0.54 μM, corresponding to a median reduction of ≥97% from pre-VORAXAZE measurements.2
VORAXAZE reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients.1
Overall primary endpoint: 45% (10/22) of patients achieved a rapid and sustained clinically important reduction in plasma MTX concentration (95% CI: 27%, 65%).1
91% (20/22) of patients who received VORAXAZE achieved a >95% reduction in plasma MTX concentrations within 15 minutes of administration that lasted for up to 8 days.1
77% (10/13) of patients with MTX levels >1 to ≤50 μM who received VORAXAZE achieved a reduction of MTX levels to ≤1 μM within 15 minutes of administration that lasted for up to 8 days.1
Results are from a single-arm, open-label study in 22 treatment-evaluable patients with markedly delayed MTX clearance secondary to AKI. The primary endpoint of the study was the proportion of patients achieving an MTX plasma concentration of ≤1 μM at 15 minutes that was sustained for up to 8 days following the initial injection.1
Review the clinical outcomes in patients with HDMTX-induced AKI after treatment with glucarpidase.
A tool designed to help clinicians understand the pharmacokinetics of HDMTX, especially regarding delayed clearance.†
This tool is a reference aid and the information contained is not intended to be a substitute for the exercise of professional judgment.
AKI, acute kidney injury; HDMTX, high-dose methotrexate; MTX, methotrexate.
To order Voraxaze® now, call 1-855-786-7292
Indication and Important Safety Information
Please see full Prescribing Information (opens in a new tab).
References